Medicare approves next generation cancer testing

The Centers for Medicare and Medicaid Services (CMS) announced they will now cover the cost of next-generation sequencing (NCS) test for patients with advanced cancer. After FDA approved a cancer diagnostic test, FoundationOne CDx, the first NGS-based in vitro diagnostic text that is a companion diagnostic for 15 targeted therapies and can detect genetic mutations in 324 genes and two genomic signatures in any solid tumor.  Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.